SCHEMBL210826

SCHEMBL210826

CC(C)(C)OC(=O)N[C@@H]1CN(C=O)CC[C@@H]1NC(=O)C(=O)Nc1ccc(Cl)s1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDM1A O60341 2/20 0.34
MAOB P27338 1/20 0.34
DRD2 P14416 3/20 0.33
PIM1 P11309 1/20 0.33
PIM3 Q86V86 1/20 0.33
PIM2 Q9P1W9 1/20 0.33
DRD3 P35462 1/20 0.33
KCNA3 P22001 1/20 0.33
EIF2AK4 Q9P2K8 1/20 0.33
CCR1 P32246 1/20 0.33
CKS1B P61024 1/20 0.33
SKP1 P63208 1/20 0.33
SKP2 Q13309 1/20 0.33
F10 P00742 2/20 0.32
JAK3 P52333 1/20 0.32
BTK Q06187 1/20 0.32
USP14 P54578 1/20 0.32
PSEN1 P49768 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL209919 0.90 KMT2A (0.34) KMT2AL3MBTL1KDM1AMAOBDRD2
SCHEMBL210382 0.86 HDAC3 (0.37) KMT2AL3MBTL1DRD2DRD3EIF2AK4
SCHEMBL210138 0.84 CCR1 (0.39) DRD2DRD3EIF2AK4CCR1USP14
SCHEMBL4270362 0.82 F10 (0.40) KMT2AL3MBTL1DRD2DRD3CCR1
SCHEMBL4270359 0.82 F10 (0.40) KMT2AL3MBTL1DRD2DRD3CCR1
SCHEMBL207173 0.80 NAMPT (0.38) KMT2ANAMPT
SCHEMBL209317 0.80 FPR2 (0.42) NAMPT
SCHEMBL207795 0.80 NPC1 (0.39) L3MBTL1EIF2AK4CCR1F10
SCHEMBL209570 0.79
SCHEMBL209539 0.78 NTRK1 (0.36) CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20090239857-A1 TRIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-24 US disclosed
US-20090239857-A1 TRIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-24 US disclosed
US-20090239857-A1 TRIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239857-A1 TRIAMINE DERIVATIVE F2, F12, F3 KMT2A 762/4885L3MBTL1 1124/4885KDM1A 1850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.